Longitudinal prescribing patterns for psychoactive medications in community‐based individuals with developmental disabilities: utilization of pharmacy records

Lott, Ira T.; McGregor, Margaret J.; Engelman, L.; Touchette, Paul E.; Tournay, Anne; Sandman, Curt A.; Fernandez, G.; Plon, Lawrence; Walsh, D.

doi:10.1111/j.1365-2788.2004.00625.x

Cited by 48 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antipsychotic and antidepressant medications are among the most frequently prescribed psychotropic medication classes in populations with IDD (Aman et al, 2003;Burd et al, 1997;Esbensen et al, 2009;Hurley et al, 2003;Lott et al, 2004;Lunsky & Elserafi, 2012;Martin, Scahill, Klin, & Volkmar, 1999;Marshall, 2004;Molyneux et al, 1999;Robertson et al, 2000;Spreat et al, 2004), yet guidelines specific to the care of these individuals do not advise beyond general psychotropic medication considerations. It is clear that population-specific, explicit guidelines for prescribing medications are necessary to aid in assessing and improving the quality of care received by this population.…”

Section: Discussionmentioning

confidence: 98%

“…Polypharmacy rates among individuals with IDD range considerably with some studies reporting rates as low as 11% and others as high as 60%, depending on the study methods (Bisconer et al, 1996;Burd et al, 1997;Lake, Balogh, & Lunsky, 2012;Lott et al, 2004;Lunsky & Elserafi, 2012;Marshall, 2004;McGillivray & McCabe, 2006;Stolker, Heerdink, Leufkens, Clerkx, & Nolen, 2001;Wood et al, 2006). Variability in polypharmacy rates highlights the need for careful consideration of how rates are derived, particularly if they are to be used as an indicator of quality of health care.…”

mentioning

confidence: 95%

“…Consequently, individuals with IDD receive more prescriptions per year and are at greater risk for polypharmacy than the general population (Straetmans, van Schrojenstein Lantman-de Valk, Schellevis, & Dinant, 2007). In particular, the prescribing of psychotropic medication is common among individuals with IDD with rates of psychotropic medication usage estimated between 28% and 89% (Bisconer, Sine, & Zhang, 1996;Burd et al, 1997;Lott et al, 2004;Molyneux, Emerson, & Caine, 1999;National Core Indicators, 2012;Spreat, Conroy, & Fullerton, 2004). Antipsychotic drugs are the most commonly prescribed psychotropic medications among individuals with IDD (Aman, Lam, & Collier-Crespin, 2003;Aman, Lam, & Van Bourgondien, 2005;Esbensen, Greenberg, Seltzer, & Aman, 2009;Hurley, Folstein, & Lam, 2003;Marshall, 2004;Molyneux et al, 1999;National Core Indicators, 2012;Robertson et al, 2000;Spreat et al, 2004).…”

mentioning

confidence: 98%

See 2 more Smart Citations

Lessons Learned From Our Elders: How to Study Polypharmacy in Populations With Intellectual and Developmental Disabilities

Stortz¹,

Lake²,

Cobigo³

et al. 2014

Intellectual and Developmental Disabilities

View full text Add to dashboard Cite

Polypharmacy is the concurrent use of multiple medications, including both psychotropic and non-psychotropic drugs. Although it may sometimes be clinically indicated, polypharmacy can have a number of negative consequences, including medication nonadherence, adverse drug reactions, and undesirable drug-drug interactions. The objective of this paper was to gain a better understanding of how to study polypharmacy among people with intellectual and developmental disabilities (IDD). To do this, we reviewed literature on polypharmacy among the elderly and people with IDD to inform future research approaches and methods on polypharmacy in people with IDD. Results identified significant variability in methods used to study polypharmacy, including definitions of polypharmacy, samples studied, analytic strategies, and variables included in the analyses. Four valuable methodological lessons to strengthen future polypharmacy research in individuals with IDD emerged. These included the use of consistent definitions of polypharmacy, the implementation of population-based sampling strategies, the development of clinical guidelines, and the importance of studying associated variables.

show abstract

Section: Discussionmentioning

confidence: 98%

mentioning

confidence: 95%

mentioning

confidence: 98%

See 1 more Smart Citation

Lessons Learned From Our Elders: How to Study Polypharmacy in Populations With Intellectual and Developmental Disabilities

Stortz¹,

Lake²,

Cobigo³

et al. 2014

Intellectual and Developmental Disabilities

View full text Add to dashboard Cite

show abstract

“…Antipsychotics have been reported to be the most common type of medication prescribed to individuals with ID (Holden and Gitlesen ; Deb and Unwin ; Matson and Neal ; Singh and Matson ; Henderson et al ; Sheehan et al ). Up to 62% of adults with ID who receive psychotropic medication receive multiple psychotropic medications (Lott et al ) often in high dosages (Cullen ; McGillivary & McCabe, 2004; Deb et al ; Taylor ). A high prevalence of psychiatric problems in adults with ID may explain some increased medication use (Chaplin ; Cooper et al ; Morgan et al ; Buckles et al ).…”

Section: Introductionmentioning

confidence: 99%

Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study

Bowring

Totsika

Hastings

et al. 2017

J intellect Disabil Res

View full text Add to dashboard Cite

show abstract

“…It is established that about 22-45% of patients with mental retardation or developmental disabilities are on psychotropic medications [4,5]. Pharmacy records suggest substantial rates of poly-pharmacy with 36% of a community sample receiving three or more psychoactive medications [6].…”

Section: Introductionmentioning

confidence: 99%

A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population

Ulzen

Powers

2008

Psychiatr Q

View full text Add to dashboard Cite

This article reviews recent evidence in the literature for the use of psychotropic and other somatic treatments in the management of patients with mental retardation (MR). The search methodology included peer-reviewed English language publications in PubMed and PsychINFO with the words Mental Retardation, Intellectual Disability, Developmental Disability and Mental Disorders/Drug Therapy or Antipsychotic medications, Psychiatric Somatic therapies, Neuroleptic Drugs, Antidepressants and Electroconvulsive Therapy from 1998 to 2008. The review revealed few randomized controlled trials on the medications frequently prescribed for patients with MR. Three RCTs of Risperidone in children, one combining adults and children and one with adults only are discussed. There was one RCT involving Quetiapine and one on Citalopram. There is little evidence to support the scope of psychotropic medication use in the MR population though the field is advancing. The contribution of psychiatric illness to challenging behaviors is not systematically addressed in the literature.

show abstract

Longitudinal prescribing patterns for psychoactive medications in community‐based individuals with developmental disabilities: utilization of pharmacy records

Cited by 48 publications

References 34 publications

Lessons Learned From Our Elders: How to Study Polypharmacy in Populations With Intellectual and Developmental Disabilities

Lessons Learned From Our Elders: How to Study Polypharmacy in Populations With Intellectual and Developmental Disabilities

Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study

A Review of Empirical Evidence of Somatic Treatment Options for the MI/DD Population

Contact Info

Product

Resources

About